The lancet oncology
-
The lancet oncology · Dec 2017
Randomized Controlled Trial Multicenter Study Comparative StudyEfficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
There are no data from prospective studies focused exclusively on patients with advanced lung and thymic carcinoids. We aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in combination, in patients with advanced carcinoids of the lung or thymus. ⋯ Novartis Pharma AG.
-
The lancet oncology · Dec 2017
Randomized Controlled Trial Multicenter Study Comparative StudyOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Olaparib combined with paclitaxel has previously shown a significant improvement in overall survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients with advanced gastric cancer, especially in those with ataxia-telangiectasia mutated protein (ATM)-negative tumours. Here, we report the primary efficacy and safety analyses from a subsequent phase 3 trial. ⋯ AstraZeneca.
-
The lancet oncology · Dec 2017
Review Comparative StudyAn integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report.
Spinal metastases are becoming increasingly common because patients with metastatic disease are living longer. The close proximity of the spinal cord to the vertebral column limits many conventional therapeutic options that can otherwise be used to treat cancer. ⋯ In this Review, we discuss the variables that should be considered during the management of these patients and review the role of each discipline and their respective management options to provide optimal care. This work is synthesised into a practical algorithm to aid clinicians in the management of patients with spinal metastasis.
-
The lancet oncology · Dec 2017
Randomized Controlled TrialBosutinib more effective than imatinib in CML.